Movatterモバイル変換


[0]ホーム

URL:


Jump to content
WikipediaThe Free Encyclopedia
Search

Ethinylandrostenediol

From Wikipedia, the free encyclopedia
Chemical compound
Pharmaceutical compound
Ethinylandrostenediol
Clinical data
Other namesSKF-2856; 17α-Ethynyl-5-androstenediol; 17α-Ethynylandrost-5-ene-3β,17-diol; 17α-Pregn-5-en-20-yne-3β,17-diol; NSC-17098
Drug classEstrogen;Progestogen;Progestin
Identifiers
  • (3S,8R,9S,10R,13S,14S,17R)-17-ethynyl-10,13-dimethyl-1,2,3,4,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthrene-3,17-diol
CAS Number
ChemSpider
ChEMBL
CompTox Dashboard(EPA)
Chemical and physical data
FormulaC21H30O2
Molar mass314.469 g·mol−1
3D model (JSmol)
  • C[C@]12CC[C@@H](CC1=CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CC[C@]4(C#C)O)C)O
  • InChI=1S/C21H30O2/c1-4-21(23)12-9-18-16-6-5-14-13-15(22)7-10-19(14,2)17(16)8-11-20(18,21)3/h1,5,15-18,22-23H,6-13H2,2-3H3/t15-,16+,17-,18-,19-,20-,21-/m0/s1
  • Key:VGJUOWGYQZYCII-TVWVXWENSA-N

Ethinylandrostenediol (developmental code nameSKF-2856), also known as17α-ethynyl-5-androstenediol, is asyntheticestrogen,progestogen, andandrogen which was never marketed.[1][2][3][4][5][6] It is the C17αethynylderivative of the androgenprecursor andprohormone5-androstenediol.[1]

Ethinylandrostenediol was firstsynthesized in the late 1930s and along with its closeanalogueethisterone (17α-ethynyltestosterone) was one of the firstprogestins (synthetic progestogens) to be developed.[7][8][9] Ethinylandrostenediol isorally active similarly to ethisterone and shows about half its progestogenicpotency.[9] Ethinylandrostenediol was an intermediate in the initialsynthesis of ethisterone.[10]

Ethinylandrostenediol showstissue selectivity in its estrogenic effects in animals and doesn't seem to have estrogenic effects in theuterus.[1] The androgenic activity of ethinylandrostenediol is weak.[9]

Anester of ethinylandrostenediol,ethandrostate (17α-ethynyl-5-androstenediol 3β-cyclohexylpropionate), has been studied clinically in men and women withprostate cancer andbreast cancer, respectively.[11][12][13][14][15]

Notable structural analogues of ethinylandrostenediol include 5-androstenediol,17α-ethynyl-3β-androstanediol,17α-ethynyl-3α-androstanediol, ethisterone (17α-ethynyltestosterone), andmethandriol (17α-methyl-5-androstenediol), as well asethinylestradiol (17α-ethynylestradiol or 17α-ethynylestra-1,3,5(10)-triene-3,17β-diol).

Affinities of estrogen receptor ligands for the ERα and ERβ
LigandOther namesRelative binding affinities (RBA, %)aAbsolute binding affinities (Ki, nM)aAction
ERαERβERαERβ
EstradiolE2; 17β-Estradiol1001000.115 (0.04–0.24)0.15 (0.10–2.08)Estrogen
EstroneE1; 17-Ketoestradiol16.39 (0.7–60)6.5 (1.36–52)0.445 (0.3–1.01)1.75 (0.35–9.24)Estrogen
EstriolE3; 16α-OH-17β-E212.65 (4.03–56)26 (14.0–44.6)0.45 (0.35–1.4)0.7 (0.63–0.7)Estrogen
EstetrolE4; 15α,16α-Di-OH-17β-E24.03.04.919Estrogen
Alfatradiol17α-Estradiol20.5 (7–80.1)8.195 (2–42)0.2–0.520.43–1.2Metabolite
16-Epiestriol16β-Hydroxy-17β-estradiol7.795 (4.94–63)50??Metabolite
17-Epiestriol16α-Hydroxy-17α-estradiol55.45 (29–103)79–80??Metabolite
16,17-Epiestriol16β-Hydroxy-17α-estradiol1.013??Metabolite
2-Hydroxyestradiol2-OH-E222 (7–81)11–352.51.3Metabolite
2-Methoxyestradiol2-MeO-E20.0027–2.01.0??Metabolite
4-Hydroxyestradiol4-OH-E213 (8–70)7–561.01.9Metabolite
4-Methoxyestradiol4-MeO-E22.01.0??Metabolite
2-Hydroxyestrone2-OH-E12.0–4.00.2–0.4??Metabolite
2-Methoxyestrone2-MeO-E1<0.001–<1<1??Metabolite
4-Hydroxyestrone4-OH-E11.0–2.01.0??Metabolite
4-Methoxyestrone4-MeO-E1<1<1??Metabolite
16α-Hydroxyestrone16α-OH-E1; 17-Ketoestriol2.0–6.535??Metabolite
2-Hydroxyestriol2-OH-E32.01.0??Metabolite
4-Methoxyestriol4-MeO-E31.01.0??Metabolite
Estradiol sulfateE2S; Estradiol 3-sulfate<1<1??Metabolite
Estradiol disulfateEstradiol 3,17β-disulfate0.0004???Metabolite
Estradiol 3-glucuronideE2-3G0.0079???Metabolite
Estradiol 17β-glucuronideE2-17G0.0015???Metabolite
Estradiol 3-gluc. 17β-sulfateE2-3G-17S0.0001???Metabolite
Estrone sulfateE1S; Estrone 3-sulfate<1<1>10>10Metabolite
Estradiol benzoateEB; Estradiol 3-benzoate10???Estrogen
Estradiol 17β-benzoateE2-17B11.332.6??Estrogen
Estrone methyl etherEstrone 3-methyl ether0.145???Estrogen
ent-Estradiol1-Estradiol1.31–12.349.44–80.07??Estrogen
Equilin7-Dehydroestrone13 (4.0–28.9)13.0–490.790.36Estrogen
Equilenin6,8-Didehydroestrone2.0–157.0–200.640.62Estrogen
17β-Dihydroequilin7-Dehydro-17β-estradiol7.9–1137.9–1080.090.17Estrogen
17α-Dihydroequilin7-Dehydro-17α-estradiol18.6 (18–41)14–320.240.57Estrogen
17β-Dihydroequilenin6,8-Didehydro-17β-estradiol35–6890–1000.150.20Estrogen
17α-Dihydroequilenin6,8-Didehydro-17α-estradiol20490.500.37Estrogen
Δ8-Estradiol8,9-Dehydro-17β-estradiol68720.150.25Estrogen
Δ8-Estrone8,9-Dehydroestrone19320.520.57Estrogen
EthinylestradiolEE; 17α-Ethynyl-17β-E2120.9 (68.8–480)44.4 (2.0–144)0.02–0.050.29–0.81Estrogen
MestranolEE 3-methyl ether?2.5??Estrogen
MoxestrolRU-2858; 11β-Methoxy-EE35–435–200.52.6Estrogen
Methylestradiol17α-Methyl-17β-estradiol7044??Estrogen
DiethylstilbestrolDES; Stilbestrol129.5 (89.1–468)219.63 (61.2–295)0.040.05Estrogen
HexestrolDihydrodiethylstilbestrol153.6 (31–302)60–2340.060.06Estrogen
DienestrolDehydrostilbestrol37 (20.4–223)56–4040.050.03Estrogen
Benzestrol (B2)114???Estrogen
ChlorotrianiseneTACE1.74?15.30?Estrogen
TriphenylethyleneTPE0.074???Estrogen
TriphenylbromoethyleneTPBE2.69???Estrogen
TamoxifenICI-46,4743 (0.1–47)3.33 (0.28–6)3.4–9.692.5SERM
Afimoxifene4-Hydroxytamoxifen; 4-OHT100.1 (1.7–257)10 (0.98–339)2.3 (0.1–3.61)0.04–4.8SERM
Toremifene4-Chlorotamoxifen; 4-CT??7.14–20.315.4SERM
ClomifeneMRL-4125 (19.2–37.2)120.91.2SERM
CyclofenilF-6066; Sexovid151–152243??SERM
NafoxidineU-11,000A30.9–44160.30.8SERM
Raloxifene41.2 (7.8–69)5.34 (0.54–16)0.188–0.5220.2SERM
ArzoxifeneLY-353,381??0.179?SERM
LasofoxifeneCP-336,15610.2–16619.00.229?SERM
OrmeloxifeneCentchroman??0.313?SERM
Levormeloxifene6720-CDRI; NNC-460,0201.551.88??SERM
OspemifeneDeaminohydroxytoremifene0.82–2.630.59–1.22??SERM
Bazedoxifene??0.053?SERM
EtacstilGW-56384.3011.5??SERM
ICI-164,38463.5 (3.70–97.7)1660.20.08Antiestrogen
FulvestrantICI-182,78043.5 (9.4–325)21.65 (2.05–40.5)0.421.3Antiestrogen
PropylpyrazoletriolPPT49 (10.0–89.1)0.120.4092.8ERα agonist
16α-LE216α-Lactone-17β-estradiol14.6–570.0890.27131ERα agonist
16α-Iodo-E216α-Iodo-17β-estradiol30.22.30??ERα agonist
MethylpiperidinopyrazoleMPP110.05??ERα antagonist
DiarylpropionitrileDPN0.12–0.256.6–1832.41.7ERβ agonist
8β-VE28β-Vinyl-17β-estradiol0.3522.0–8312.90.50ERβ agonist
PrinaberelERB-041; WAY-202,0410.2767–72??ERβ agonist
ERB-196WAY-202,196?180??ERβ agonist
ErteberelSERBA-1; LY-500,307??2.680.19ERβ agonist
SERBA-2??14.51.54ERβ agonist
Coumestrol9.225 (0.0117–94)64.125 (0.41–185)0.14–80.00.07–27.0Xenoestrogen
Genistein0.445 (0.0012–16)33.42 (0.86–87)2.6–1260.3–12.8Xenoestrogen
Equol0.2–0.2870.85 (0.10–2.85)??Xenoestrogen
Daidzein0.07 (0.0018–9.3)0.7865 (0.04–17.1)2.085.3Xenoestrogen
Biochanin A0.04 (0.022–0.15)0.6225 (0.010–1.2)1748.9Xenoestrogen
Kaempferol0.07 (0.029–0.10)2.2 (0.002–3.00)??Xenoestrogen
Naringenin0.0054 (<0.001–0.01)0.15 (0.11–0.33)??Xenoestrogen
8-Prenylnaringenin8-PN4.4???Xenoestrogen
Quercetin<0.001–0.010.002–0.040??Xenoestrogen
Ipriflavone<0.01<0.01??Xenoestrogen
Miroestrol0.39???Xenoestrogen
Deoxymiroestrol2.0???Xenoestrogen
β-Sitosterol<0.001–0.0875<0.001–0.016??Xenoestrogen
Resveratrol<0.001–0.0032???Xenoestrogen
α-Zearalenol48 (13–52.5)???Xenoestrogen
β-Zearalenol0.6 (0.032–13)???Xenoestrogen
Zeranolα-Zearalanol48–111???Xenoestrogen
Taleranolβ-Zearalanol16 (13–17.8)140.80.9Xenoestrogen
ZearalenoneZEN7.68 (2.04–28)9.45 (2.43–31.5)??Xenoestrogen
ZearalanoneZAN0.51???Xenoestrogen
Bisphenol ABPA0.0315 (0.008–1.0)0.135 (0.002–4.23)19535Xenoestrogen
EndosulfanEDS<0.001–<0.01<0.01??Xenoestrogen
KeponeChlordecone0.0069–0.2???Xenoestrogen
o,p'-DDT0.0073–0.4???Xenoestrogen
p,p'-DDT0.03???Xenoestrogen
Methoxychlorp,p'-Dimethoxy-DDT0.01 (<0.001–0.02)0.01–0.13??Xenoestrogen
HPTEHydroxychlor;p,p'-OH-DDT1.2–1.7???Xenoestrogen
TestosteroneT; 4-Androstenolone<0.0001–<0.01<0.002–0.040>5000>5000Androgen
DihydrotestosteroneDHT; 5α-Androstanolone0.01 (<0.001–0.05)0.0059–0.17221–>500073–1688Androgen
Nandrolone19-Nortestosterone; 19-NT0.010.2376553Androgen
DehydroepiandrosteroneDHEA; Prasterone0.038 (<0.001–0.04)0.019–0.07245–1053163–515Androgen
5-AndrostenediolA5; Androstenediol6173.60.9Androgen
4-Androstenediol0.50.62319Androgen
4-AndrostenedioneA4; Androstenedione<0.01<0.01>10000>10000Androgen
3α-Androstanediol3α-Adiol0.070.326048Androgen
3β-Androstanediol3β-Adiol3762Androgen
Androstanedione5α-Androstanedione<0.01<0.01>10000>10000Androgen
Etiocholanedione5β-Androstanedione<0.01<0.01>10000>10000Androgen
Methyltestosterone17α-Methyltestosterone<0.0001???Androgen
Ethinyl-3α-androstanediol17α-Ethynyl-3α-adiol4.0<0.07??Estrogen
Ethinyl-3β-androstanediol17α-Ethynyl-3β-adiol505.6??Estrogen
ProgesteroneP4; 4-Pregnenedione<0.001–0.6<0.001–0.010??Progestogen
NorethisteroneNET; 17α-Ethynyl-19-NT0.085 (0.0015–<0.1)0.1 (0.01–0.3)1521084Progestogen
Norethynodrel5(10)-Norethisterone0.5 (0.3–0.7)<0.1–0.221453Progestogen
Tibolone7α-Methylnorethynodrel0.5 (0.45–2.0)0.2–0.076??Progestogen
Δ4-Tibolone7α-Methylnorethisterone0.069–<0.10.027–<0.1??Progestogen
3α-Hydroxytibolone2.5 (1.06–5.0)0.6–0.8??Progestogen
3β-Hydroxytibolone1.6 (0.75–1.9)0.070–0.1??Progestogen
Footnotes:a = (1)Binding affinity values are of the format "median (range)" (# (#–#)), "range" (#–#), or "value" (#) depending on the values available. The full sets of values within the ranges can be found in the Wiki code. (2) Binding affinities were determined via displacement studies in a variety ofin-vitro systems withlabeled estradiol and humanERα andERβ proteins (except the ERβ values from Kuiper et al. (1997), which are rat ERβ).Sources: See template page.

References

[edit]
  1. ^abcTan VY (2010).Characterization of the estrogenic activity of a synthetic adrenal steroid 17-α ethinyl androstenediol and its potential use in hormone replacement therapy (Ph.D. thesis).hdl:10356/45321.
  2. ^Beyler AL, Clinton RO (June 1956). "Uterine growth stimulating and testicular growth suppressing activities of 17alpha-ethinylandrostane-3beta, 17beta-diol, its delta 5-analog and derivatives".Proc. Soc. Exp. Biol. Med.92 (2):404–8.doi:10.3181/00379727-92-22493.PMID 13350363.S2CID 87469965.
  3. ^Masson G, Selye H (1945). "Additional steroids with luteoid activity".Journal of Pharmacology and Experimental Therapeutics.84 (1):46–52.doi:10.1016/S0022-3565(25)08059-0.JSTOR 1671439.
  4. ^Overbeek GA (1948). "Luteoid activity of ethinyl-androstenediol".Acta Brevia Neerl Physiol Pharmacol Microbiol e A.15 (5–7): 68.PMID 18873577.
  5. ^Mardones E, Iglesias R, Lipschutz A (February 1956). "The antiluteinizing potency of five derivatives of progesterone".Endocrinology.58 (2):212–9.doi:10.1210/endo-58-2-212.PMID 13285465.
  6. ^Neumann F (1968). "Chemische Konstitution und pharmakologische Wirkung".Die Gestagene. Handbuch der experimentellen Pharmakologie / Handbook of Experimental Pharmacology. Springer. pp. 680–1025.doi:10.1007/978-3-642-99941-3_6.ISBN 978-3-642-99942-0.
  7. ^Stavely HE (1939). "Preparation of a Pregnane Compound from Dehydroandrosterone".Journal of the American Chemical Society.61 (1):79–80.Bibcode:1939JAChS..61...79S.doi:10.1021/ja01870a023.ISSN 0002-7863.
  8. ^Stavely HE (1940). "The Preparation of Δ5-Pregnenediol-3,17-one-20 from Δ5-17-Ethynyl-androstenediol-3,17".Journal of the American Chemical Society.62 (3):489–491.Bibcode:1940JAChS..62..489S.doi:10.1021/ja01860a007.ISSN 0002-7863.
  9. ^abcEmmens CW (22 October 2013).Hormone Assay. Elsevier Science. pp. 422–.ISBN 978-1-4832-7286-3.
  10. ^Sneader W (23 June 2005).Drug Discovery: A History. John Wiley & Sons. pp. 200–.ISBN 978-0-471-89979-2.
  11. ^Ahlem C, Kennedy M, Page T, Bell D, Delorme E, Villegas S, Reading C, White S, Stickney D, Frincke J (February 2012). "17α-alkynyl 3α, 17β-androstanediol non-clinical and clinical pharmacology, pharmacokinetics and metabolism".Invest New Drugs.30 (1):59–78.doi:10.1007/s10637-010-9517-0.PMID 20814732.S2CID 24785562.
  12. ^Shipley EG (1962)."Anti-gonadotropic steroids, inhibition of ovulation and mating". In Dorfman RI (ed.).Bioassay. Elsevier. pp. 179–274.ISBN 978-1-4832-7276-4.{{cite book}}:ISBN / Date incompatibility (help)
  13. ^Boccabella A, Bakritges C (January 1956). "Effects of ethandrostate on pituitary and sex organs of rats".Anatomical Record.124 (2): 260.
  14. ^Clinton R, Neumann H, Laskowski S, Christiansen R (1957). "Esters of 17α-Ethinyl-androstane-3β,17β-diol and 17 α-Ethinylandrost-5-ene-3β, 17β-diol".The Journal of Organic Chemistry.22 (4):473–475.doi:10.1021/jo01355a627.ISSN 0022-3263.
  15. ^Olson KB, Frawley TF, Stein AA, Shields D (1958). "Ethandrostate: endocrine effects and studies in treatment of cancer".Cancer.11 (3):537–45.doi:10.1002/1097-0142(195805/06)11:3<537::aid-cncr2820110313>3.0.co;2-w.PMID 13523561.S2CID 738607.


ARTooltip Androgen receptor
Agonists
SARMsTooltip Selective androgen receptor modulator
Antagonists
GPRC6A
Agonists
ERTooltip Estrogen receptor
Agonists
Mixed
(SERMsTooltip Selective estrogen receptor modulators)
Antagonists
GPERTooltip G protein-coupled estrogen receptor
Agonists
Antagonists
Unknown
PRTooltip Progesterone receptor
Agonists
Mixed
(SPRMsTooltip Selective progesterone receptor modulators)
Antagonists
mPRTooltip Membrane progesterone receptor
(PAQRTooltip Progestin and adipoQ receptor)
Agonists
Antagonists
Retrieved from "https://en.wikipedia.org/w/index.php?title=Ethinylandrostenediol&oldid=1308410296"
Categories:
Hidden categories:

[8]ページ先頭

©2009-2025 Movatter.jp